Isamu Furosako
About Isamu Furosako
Isamu Furosako is the Director of Global Commercial Information Technology Japan at Bristol-Myers Squibb, with extensive experience in business development and IT solutions within the pharmaceutical industry.
Company
Isamu Furosako is currently employed at Bristol-Myers Squibb, a global biopharmaceutical company. He holds the position of Director, Global Commercial Information Technology Japan, and is based in New Jersey, United States. Bristol-Myers Squibb is renowned for its innovations in pharmaceutical and healthcare solutions, where Isamu has been contributing since August 2014.
Education and Expertise
Isamu Furosako studied at Bond University, where he completed a Master of Business Administration (MBA) in Business. His academic background provided a solid foundation for his extensive career in business development and IT solutions within the pharmaceutical industry. His MBA has equipped him with the strategic and analytical skills necessary for understanding and implementing commercial IT systems on a global scale.
Professional Background
Isamu Furosako has a diverse and rich professional background in the pharmaceutical and healthcare sectors. Before his current role, he served at Veeva Systems as a Senior Sales Consultant for Veeva Vault from 2013 to 2014 in Pleasanton, California. Prior to that, he was a Senior Manager of New Business Development at Cegedim Relationship Management in Aquitaine, France, from 2012 to 2013. He also held the role of Associate Director of Business Solution Japan at Iqvia in Durham, North Carolina, from 2008 to 2011.
Industry Experience
With extensive experience in business development and IT solutions, Isamu Furosako has a deep understanding of commercial IT systems and their applications in global markets. His roles have spanned multiple countries including the United States, France, and Japan, reflecting his international expertise. His background in sales consulting and new business development is particularly strong in the healthcare and life sciences sectors.